Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Axsome Therapeutics (NASDAQ:AXSM) had its price target boosted by stock analysts at Morgan Stanley from $247.00 to $249.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley‘s price target suggests a potential upside of 73.69% from the stock’s previous close.

AXSM has been the subject of several other research reports. UBS Group dropped their price target on shares of Axsome Therapeutics from $256.00 to $239.00 and set a “buy” rating for the company in a research note on Tuesday. Needham & Company LLC increased their price objective on Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Guggenheim reduced their price objective on Axsome Therapeutics from $275.00 to $250.00 and set a “buy” rating on the stock in a research note on Tuesday. Mizuho lifted their target price on Axsome Therapeutics from $306.00 to $316.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, HC Wainwright reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $269.89.

Axsome Therapeutics Trading Up 5.4%

AXSM traded up $7.35 during mid-day trading on Tuesday, hitting $143.36. 804,537 shares of the stock were exchanged, compared to its average volume of 781,953. The company has a market cap of $7.51 billion, a PE ratio of -38.21 and a beta of 0.86. Axsome Therapeutics has a 1-year low of $123.00 and a 1-year high of $260.19. The company has a current ratio of 1.43, a quick ratio of 1.34 and a debt-to-equity ratio of 1.52. The firm’s fifty day moving average is $183.33 and its two-hundred day moving average is $198.74.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.38. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The business had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. During the same quarter last year, the firm posted ($0.94) earnings per share. The business’s revenue for the quarter was up 51.9% compared to the same quarter last year. Equities analysts forecast that Axsome Therapeutics will post -3.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total value of $2,086,500.00. Following the transaction, the chief operating officer directly owned 10,000 shares in the company, valued at approximately $2,086,500. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Herriot Tabuteau sold 45,004 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $212.01, for a total value of $9,541,298.04. Following the completion of the transaction, the chief executive officer owned 7,229 shares in the company, valued at $1,532,620.29. This trade represents a 86.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 59,664 shares of company stock worth $12,624,805. 20.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. BlackRock Inc. acquired a new position in shares of Axsome Therapeutics during the 2nd quarter valued at about $759,695,000. Hillsdale Investment Management Inc. purchased a new position in shares of Axsome Therapeutics during the 1st quarter worth about $9,019,000. OneDigital Investment Advisors LLC acquired a new stake in shares of Axsome Therapeutics in the second quarter worth approximately $1,906,000. Baird Financial Group Inc. acquired a new stake in shares of Axsome Therapeutics in the second quarter worth approximately $2,497,000. Finally, Lisanti Capital Growth LLC purchased a new stake in Axsome Therapeutics in the second quarter valued at approximately $5,097,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Axsome reported third-quarter revenue of $259.7 million, up 51.9% year over year and ahead of the $249.2 million consensus estimate. The company’s adjusted loss of $0.25 per share was substantially better than the expected $0.63 loss and improved from a $0.94 loss a year earlier. Axsome third-quarter results
• Positive Sentiment: Management highlighted sales growth across key brands and pipeline milestones expected in 2027, supporting the longer-term growth narrative. Axsome sales and pipeline update
• Neutral Sentiment: Axsome will participate in several November healthcare investor conferences, including events hosted by Guggenheim, Wolfe Research, Truist and UBS. These presentations could provide further updates on product launches and the pipeline, but do not represent a new operating development. Axsome upcoming investor conferences
• Negative Sentiment: Market concerns about slower-than-expected AUVELITY adoption in Alzheimer’s care appear to outweigh the quarterly beat. Reports indicate incremental growth was driven more by depression prescriptions for patients under 65 than by Alzheimer’s-related prescriptions, raising questions about the durability of near-term growth. AUVELITY launch concerns
• Negative Sentiment: Several analysts lowered their price targets following the results: RBC to $273, Guggenheim to $250, UBS to $239 and Baird to $220, while maintaining positive ratings. The cuts suggest analysts still see substantial upside but are reducing estimates to reflect launch execution and valuation risks. UBS Axsome price-target reduction

About Axsome Therapeutics

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.